Dr Lal Pathlabs Ltd (LALPATHLAB) Q1 FY27 Results Analysis: PAT Jumps 28%, Acquisition Spree Continues

Dr Lal Pathlabs Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 797.70 Cr (+19.10% YoY) and PAT growth of +28.02% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Q1 revenue grew 19.1% YoY to Rs.797.7 Cr, with EBITDA margin expanding 232 bps to 31.0%. PAT attributable to owners rose 28% YoY. The company completed one acquisition and proposed another, expanding its network, though the sustainability of the elevated margin remains to be seen.

Key Investment Insights

Key Positives

• Revenue grew 19.1% YoY to Rs.797.7 Cr, accelerating from FY26 run-rate of ~12%.
• EBITDA margin expanded 232 bps YoY to 31.03%.
• PAT attributable to owners grew 28.02% YoY to Rs.169.5 Cr.
• Employee benefits ratio compressed 192 bps YoY to 16.64% of revenue.
• Acquisition of Shahbazkers Diagnostic Centre completed, expanding network.
• Proposed acquisition of 80% stake in Sunshine Healthcare (Ghana) for up to Rs.380 Mn.

Risk Factors

• Channel-partner fee ratio edged up to 14.52% from 14.30% YoY, a potential margin drag if growth slows.